Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 10,357 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all

Conditions: Hereditary Angioedema (HAE)
Interventions: Deucrictibant; Drug
Lead sponsor: Pharvaris Netherlands B.V.; Industry
Eligibility: 12 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 10 more

Conditions: Thalassemia, Sickle Cell Disease, Healthy Controls
Interventions: Hydroxyurea, Acetazolamide; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 7 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Myotonic Dystrophy 1, DM1
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • Denver, Colorado + 7 more

Conditions: Recessive Dystrophic Epidermolysis Bullosa
Interventions: PTR-01; Drug
Lead sponsor: Phoenix Tissue Repair, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Redwood City, California • Aurora, Colorado

Conditions: Cystic Fibrosis, Lung Diseases
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Up to 100 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Niemann-Pick Disease, Type C
Interventions: arimoclomol, Placebo; Drug
Lead sponsor: ZevraDenmark; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 2
States / cities: Oakland, California • Rochester, Minnesota

Conditions: End Stage Renal Disease, Arteriovenous Fistula, Arteriovenous Graft
Interventions: Arteriovenous Fistula (AVF), Arteriovenous Graft (AVG); Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ebola Virus Disease, Marburg Virus Disease
Interventions: cAd3-Marburg, cAd3-EBO-S; Biological
Lead sponsor: Albert B. Sabin Vaccine Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Congenital Diaphragmatic Hernia, Fetal Surgery, Pulmonary Hypoplasia
Interventions: Fetoscopic Endoluminal Tracheal Occlusion; Procedure
Lead sponsor: University Hospital, Gasthuisberg; Other
Eligibility: 18 Years and older · Female only
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis; Biological · Procedure
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more

Conditions: Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis With Intestinal Manifestations
Interventions: Low Glycemic Load Diet; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiac Amyloidosis
Interventions: Cardiac amyloidosis deep learning model; Device
Lead sponsor: Pierre Elias; Other
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypophosphatasia
Interventions: Whole Genome Sequencing; Genetic
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: Not listed
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Cystic Fibrosis
Interventions: Broccoli sprouts; Dietary Supplement
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 49 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pompe Disease
Interventions: Albuterol, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dermatitis, Atopic
Interventions: Pimecrolimus plus topical corticosteroid (TCS), Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS); Drug
Lead sponsor: Novartis; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 13
States / cities: Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Surfactant; Drug
Lead sponsor: Sood, Beena G., MD, MS; Individual
Eligibility: Up to 24 Hours
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Glycogen Storage Disease Type IV, Adult Polyglucosan Body Disease, GSD4, GSD IV, APBD
Interventions: No intervention; Other
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2035
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Skin Laxity, Wrinkle, Skin Condition
Interventions: Profound Matrix; Device
Lead sponsor: Candela Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 4
States / cities: Jacksonville, Florida • Marlborough, Massachusetts • Fayetteville, North Carolina + 1 more

Conditions: Stress Reduction
Interventions: FertiStrong App; Behavioral
Lead sponsor: Fertility Centers of Illinois; Other
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atrial Fibrillation, Stroke, Valve Disease, Heart, Atrial Septal Defect, Patent Foramen Ovale, Mitral Valve Disease, Tricuspid Valve Disease, Aortic Valve Disease
Interventions: ICE Image guidance; Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Pediatric, Cardiac Surgery
Interventions: PC/SMART cardiopulmonary bypass circuit, PMEA modified cardiopulmonary bypass circuit, Standard of care uncoated cardiopulmonary bypass circuit; Device
Lead sponsor: Emory University; Other
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: ABCA4 Retinopathy, Stargardt Disease, Retinal Dystrophy, Retinal Degeneration
Interventions: Metformin hydrochloride; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 12 Years to 100 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 2
States / cities: Bethesda, Maryland • Ann Arbor, Michigan

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 4,392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Raleigh, North Carolina

Search by objective public record fields.

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia

Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)

A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa

Gene Modifiers of Cystic Fibrosis Lung Disease

Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C

Trial of Fistula Versus Graft in Elderly Patients

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

Fetal Surgery for Moderate Left Sided Congenital Diaphragmatic Hernia.

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

A Pilot Study of a Low Glycemic Load Diet in Adults With Cystic Fibrosis

Cardiac Amyloidosis Discovery Trial

United States Hypophosphatasia Molecular Research Center

Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation

Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease

Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis

Aerosolized Surfactant in Neonatal RDS

GBE Deficiency (GSD IV and APBD) Natural History Study

Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System

The Impact of a Self-help Coping App on Distress Levels in Men Experiencing Infertility

Philips Intracardiac Echocardiography (ICE) Clinical Registry

Cardiopulmonary Circuits in the Pediatric Population

Oral Metformin for Treatment of ABCA4 Retinopathy

Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina